Literature DB >> 12243504

Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome.

Abelardo Moreno1, Agustín Escobedo, Enrique Benito, Jose Ma Serra, Anna Gumà, Francisco Riu.   

Abstract

The pathologic changes associated to response to primary chemotherapy in a series of 303 operable breast cancers are evaluated and correlated to patients' follow-up (interval free of disease and survival). In our series, the incidence of microscopic changes related to chemotherapy is 43.9%. Tumor replacement by loose fibrosis is the most common pathologic event. In most cases, the intensity of fibrotic change is proportional to the degree of clinical-mammographic reduction of the tumor mass. However, some discrepancies exist in the sense of absence of microscopic changes in cases of well-documented mammographic reduction as well as in cases without clinical reduction but with large areas of chemotherapy-related fibrosis. The presence of pathologic response is significantly associated with better survival rate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243504     DOI: 10.1023/a:1019607924403

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Authors:  Rosalind P Candelaria; Beatriz E Adrada; Deanna L Lane; Gaiane M Rauch; Stacy L Moulder; Alastair M Thompson; Roland L Bassett; Elsa M Arribas; Huong T Le-Petross; Jessica W T Leung; David A Spak; Elizabeth E Ravenberg; Jason B White; Vicente Valero; Wei T Yang
Journal:  Ultrasound Med Biol       Date:  2022-03-14       Impact factor: 2.998

2.  [Morphological response to therapy of breast carcinoma].

Authors:  F Länger; H-J Lück; H H Kreipe
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

Review 3.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

4.  Diagnosing breast cancer using Raman spectroscopy: prospective analysis.

Authors:  Abigail S Haka; Zoya Volynskaya; Joseph A Gardecki; Jon Nazemi; Robert Shenk; Nancy Wang; Ramachandra R Dasari; Maryann Fitzmaurice; Michael S Feld
Journal:  J Biomed Opt       Date:  2009 Sep-Oct       Impact factor: 3.170

5.  HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy.

Authors:  Catalina Falo; Abelardo Moreno; Mar Varela; Belen Lloveras; Agnès Figueras; Agustín Escobedo
Journal:  J Cancer Res Clin Oncol       Date:  2007-01-24       Impact factor: 4.322

Review 6.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

7.  Histopathologic changes following neoadjuvant chemotherapy in various malignancies.

Authors:  Divya Sethi; Rajeev Sen; Sanjeev Parshad; Sheena Khetarpal; Monika Garg; Jyotsna Sen
Journal:  Int J Appl Basic Med Res       Date:  2012-07

8.  Detection of Post-Therapeutic Effects in Breast Carcinoma Using Hard X-Ray Index of Refraction Computed Tomography - A Feasibility Study.

Authors:  Susanne Grandl; Anikó Sztrókay-Gaul; Alberto Mittone; Sergey Gasilov; Emmanuel Brun; Alberto Bravin; Doris Mayr; Sigrid D Auweter; Karin Hellerhoff; Maximilian Reiser; Paola Coan
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.